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mentioned a reference that actually indicated that dichotomiza-
tion of the continuous adherence variable was inappropriate.
CONCLUSION: MPR and gap between reﬁlls were the most
commonly used measures of medication adherence. Almost one
third of the studies used dichotomous measures. A medication
adherence of 80% of the therapy was typically indicated as the
cut-point between adherence and non-adherence. There is no
accepted clinical or pharmacological rationale for medication
adherence threshold selection. The use of continuous variables to
measure medication adherence is recommended.
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OBJECTIVE: To examine the impact of copayments or brand
named drug as well as other factors on medication persistence
from a large U.S. employer. METHODS: We analyzed medical
and pharmaceutical claims data from 2002 through 2006 for
new users prescribed a single agent for either three antihyperten-
sive (angiotensin converting enzyme inhibitors, beta blockers,
and calcium blockers) or two anti-diabetic (biguanides and sul-
fonylureas) therapeutic classes. Nonpersistence with medication
was measured using three methods: medication possession ratio
(MPR) <0.8; number of days to the ﬁrst drug coverage gap of
15 days; and number of days to drug discontinuation (90
days gap). Logistic regression and Cox proportional hazard
models were performed to evaluate the association between the
potential risk factors and the likelihood of medication nonper-
sistence. RESULTS: A total of 1422 members with 12 months
claim data following the ﬁrst drug ﬁlled were identiﬁed. Fifty-
four percent were male with a mean age 52.8  8.0 years, and
44% initially used a brand named drug. The logistic regression
results revealed that increasing age per year (OR = 0.966; 95%
CI = 0.952–0.979), PPO (OR = 0.424; CI = 0.261–0.689) or
HMO insurance (OR = 0.440; CI = 0.262–0.739) as compared
to conventional fee for service coverage were less likely to have
MPR < 0.8. Management workers (OR = 1.475; CI = 1.113–
1.954) were more likely to have MPR < 0.8. MPR < 0.8 was not
associated with use of an initial brand named drug, comorbidi-
ties, or health care utilization in the six months prior to initiating
medication therapy. The Cox models showed that the risk for
a gap increased 1.1% (HR = 1.011, CI = 1.004–1.019), and
medication discontinuation increased 0.9% (HR = 1.009,
CI = 1.003–1.014) with each $1 increase in initial drug copay-
ments. CONCLUSION: Younger employees, management
workers, conventional fee for service insurance coverage, and an
increase in initial copayments are factors predictive of greater
risk for noncompliance with medications. These data may be
helpful for employers when making drug beneﬁt design decisions.
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OBJECTIVE: The purpose of this study was to quantify the
extent of nonadherence and to determine the rate of switching
across organ rejection drugs. METHODS: Blinded prescription
data from 35 national retail pharmacy chains was analyzed for
13,250 patients taking sirolimus, cyclosporine, and tacrolimus.
Cumulative drug consumption (total days supply) during the one
year follow up period was employed as the measure of adher-
ence. Kaplan Meier estimates of survival (persistence) curves
were used to assess the time to discontinuation and to calculate
the one-year rate of discontinuation. Baseline patient character-
istics, including age, gender, geographic region, median income,
index quantity dispensed, population density, co-pay, and index
reﬁll and days supply prescribed were analyzed. RESULTS:
Adherence data across these drugs showed that sirolimus,
cyclosporine, and tacrolimus patients on average obtained 5.5
(4.5), 5.2 (5.4), and 6.5 (5.3) ﬁlls, and 170.8 (132.9),
159.2 (163.96), and 194.8 (159.6) days supply of medication
over 12 months, respectively. At day 60, 41% of sirolimus, 44%
of tacrolimus, and 52% of cyclosporine patients discontinued
therapy. After 6 months, 68% of tacrolimus and sirolimus and
77% of cyclosporine patients discontinued therapy. The rate of
switching to another agent was 6.5% for sirolimus, 1.4% for
tacrolimus, and 1.1% for cyclosporine at month 6, and 10.9%,
2.3%, and 1.8% at month 12, respectively. CONCLUSION:
Even though organ transplant drugs are vital for transplant
patients, 68% to 77% of patients discontinue therapy after 6
months. Research has showed that nonadherence to immunosup-
pressive therapy is the leading cause of organ rejection, organ
loss, and death. Efforts to maintain patients on these drugs are
needed in the beginning of and throughout treatment to avoid
organ rejection.
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OBJECTIVE: To determine the demographic, insurance, and
health status predictors of noncompliant cost-cutting behavior
among U.S. adults. METHODS: Data were from quarters one
and two of the 2007 National Health and Wellness Survey
(NHWS), an internet-based study of the health care attitudes,
behaviors, disease states, and outcomes of a demographically
representative sample of adults age 18+. Noncompliant cost-
cutting behaviors were deﬁned as taking less medication than
prescribed, cutting tablets in half, or buying fewer tablets. Logis-
tic regression analysis was used to determine the demographic,
insurance, and health status predictors of noncompliant cost-
cutting behavior. RESULTS: Of the 42,010 NHWS respondents,
12% reported some noncomplaint cost-cutting behavior, more
speciﬁcally 7% reported taking less medication than prescribed,
6% reported cutting tablets in half, and 2% reported buying
fewer tablets. Signiﬁcant predictors of greater likelihood of
noncompliant cost-cutting behavior include being non-white
(OR = 1.182, p < 0.001), having a college degree (OR = 1.094,
p = 0.009), having individual or family insurance purchased
directly (OR = 1.300, p < 0.001), purchasing medications
outside the U.S. (OR = 3.862, p < 0.001), number of physical
comorbid conditions (OR = 1.176, p < 0.001), having a psychi-
atric condition (OR = 1.620, p < 0.001), currently smoke
(OR = 1.137, p < 0.001), and body mass index (OR = 1.006,
p = 0.007). Signiﬁcant predictors of lesser likelihood of noncom-
pliant cost-cutting behavior include age (OR = 0.996, p = 0.001),
having insurance through the Veteran’s Administration
(OR = 0.514, p < 0.001), and having Rx coverage (OR = 0.808,
p < 0.001). Gender, marital status, annual income greater than
$50,000, number of adults in household, and insurance through
employer, Medicaid, or Medicare were not signiﬁcant predictors
of non-compliant cost cutting behavior. CONCLUSION: There
are several signiﬁcant predictors of noncompliant cost-cutting
behavior. Knowing these predictors may help in targeting cost
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savings and compliance programs at those who need them the
most.
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OBJECTIVE: To quantify the effects of noncompliant cost-
cutting behavior on health-related quality of life (HRQOL),
work productivity, and activity impairment among U.S. adults.
METHODS: Data were from quarters one and two of the 2007
National Health and Wellness Survey (NHWS), an internet-
based study of the health care attitudes, behaviors, disease states,
and outcomes of a demographically representative sample of
adults age 18+. Noncompliant cost-cutting behaviors were
deﬁned as taking less medication than prescribed, cutting tablets
in half, or buying fewer tablets. Outcomes measures include the
SF12V2 and the Work Productivity and Activity Impairment
(WPAI) questionnaire. Linear regression analysis was used to
control for gender, age, race, marital status, education, and
comorbid conditions. RESULTS: Of the 42,010 NHWS respon-
dents, 7% took less medication than prescribed, 6% cut tablets
in half, and 2% bought fewer tablets. Controlling for potential
confounders, SF12 physical and mental summary scores are sig-
niﬁcantly lower for those taking less medication (2.3 and 2.5
points lower, p < 0.001), those cutting tablets in half (0.9 and 1.1
points, p < 0.001), and those buying fewer tablets (1.5 and 1.6,
p < 0.001). Controlling for potential confounders, WPAI overall
work loss and WPAI activity impairment are signiﬁcantly lower
for those taking less medication (10.3 and 7.2 points lower,
p < 0.001), those cutting tablets in half (11.2 and 5.3 points, p <
0.001), and those buying fewer tablets (15.8 and 8.2, p < 0.001).
CONCLUSION: Noncompliant cost-cutting behavior negatively
affects humanistic outcomes. By decreasing this behavior cost
savings and compliance programs should have a positive effect
on humanistic outcomes.
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OBJECTIVE: To quantify the effects of noncompliant cost-
cutting behavior on health-related quality of life (HRQOL),
work productivity, and activity impairment among adults in
Europe. METHODS: Data were from the 2007 European
National Health and Wellness Survey (NHWS), a self-
administered, Internet-based study of the health care attitudes,
behaviors, disease states, and outcomes of a demographically
representative sample of adults age 18+ across ﬁve European
countries: France, Germany, Italy, Spain, and the UK. Three
noncompliant cost-cutting behaviors were analyzed: taking less
medication than prescribed, cutting tablets in half, and buying
fewer tablets. Outcomes measures included the SF12V2 and the
Work Productivity and Activity Impairment (WPAI) question-
naire. Linear regression analysis was used to adjust for gender,
age, country of residence, marital status, education, and physi-
cal and psychiatric comorbid conditions. RESULTS: Of the
53,524 NHWS respondents, 3.1% took less medication than
prescribed, 2.1% cut tablets in half, and 1.6% bought fewer
tablets. Unadjusted results showed a negative association
between these behaviors and indirect costs. Adjusting for
potential confounders, SF12 physical and mental summary
scores were signiﬁcantly lower for those taking less medication
(2.2 and 2.4 points lower, p < 0.001), those cutting tablets in
half (1.8 and 2.0 points lower, p < 0.001), and those buying
fewer tablets (1.8 and 2.3 points lower, p < 0.001). Adjusting
for potential confounders, WPAI overall work loss and WPAI
activity impairment were signiﬁcantly lower for those taking
less medication (11.0 and 9.2 points lower, p < 0.001), those
cutting tablets in half (13.4 and 6.3 points lower, p < 0.001),
and those buying fewer tablets (10.1 and 7.7 points lower,
p < 0.001). CONCLUSION: Noncompliant cost-cutting behav-
ior negatively affects indirect costs, speciﬁcally HRQOL, work
productivity, and activity impairment. By decreasing this behav-
ior cost savings and compliance programs should have a posi-
tive effect on humanistic outcomes.
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OBJECTIVE: The U.S. Centers for Medicare and Medicaid Ser-
vices (CMS) generally pays for non-institutional-based services
and supplies “incident to” a physician’s professional service. This
study explores the concept of incident-to, the regulations and
guidance surrounding its use and presents practical consider-
ations for physicians. METHODS: Incident-to guidance pro-
vided by CMS was collected, arranged in order of issuance,
abstracted and analyzed. A compilation of relevant resources, a
glossary and checklist tool were also created as part of the
project. RESULTS: Federal regulations at 42 CFR 410.26(b)
specify criteria for “incident to” services. Medicare Part B pays
for services and supplies incident to the service of a physician,
including drugs or biologicals that are not usually self-
administered. The services and supplies must be furnished in a
non-institutional setting to non-institutional patients and be of
an integral, though incidental, part of the service of a physician
in the course of diagnosis or treatment of an injury or illness.
They are also provided without charge or included in the bill of
a physician. Such services are typically performed by non-
physician staff however require direct personal supervision by the
physician. The U.S Ofﬁce of the Inspector General (OIG) has
announced incident-to services as an area of study in their 2008
Work Plan. CONCLUSION: The concept of incident-to services
is commonly misunderstood and may therefore present a Medi-
care compliance risk for physicians. It is essential for physicians
and their practice decision-makers to understand and apply the
CMS regulations surrounding incident-to services in order to
appropriately bill and be reimbursed by Medicare for the provi-
sion of Part B separately payable drugs in non-institutional
settings.
HEALTH CARE USE & POLICY STUDIES—
Consumer Role in Health Care
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OBJECTIVE: With the withdrawal of Zelnorm, recall of prod-
ucts such as Ranbaxy’s generic gabapentin, and the increase in
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